Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;6(9):433-441.
doi: 10.5194/jbji-6-433-2021. eCollection 2021.

Immunological evaluation of patients with orthopedic infections: taking the Cierny-Mader classification to the next level

Affiliations

Immunological evaluation of patients with orthopedic infections: taking the Cierny-Mader classification to the next level

Janet D Conway et al. J Bone Jt Infect. .

Abstract

Introduction: Cierny-Mader osteomyelitis classification is used to label A, B, or C hosts based on comorbidities. This study's purpose was to define the "true" host status of patients with orthopedic infection using serologic markers to quantify the competence of their immune system while actively infected. Methods: Retrospective chart review identified patients at a single-surgeon practice who were diagnosed with orthopedic infection between September 2013 and March 2020 and had immunological laboratory results. All patients were A or B hosts who underwent surgery to eradicate infection. Medical history, physical examination, and Cierny-Mader classification were recorded. Laboratory results included complement total, C3, C4, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin E (IgE), rheumatoid factor, and antineutrophil cytoplasmic antibodies (ANCA) panel. Clinically significant results were defined as flagged abnormal. Normal complement levels and normal IgG levels were considered abnormal when infection was present. Results: Of 105 patients, 99 (94 %) had documented lab abnormalities. Clinically significant abnormalities were found in 33 of 34 (97 %) type-A hosts and 66 of 71 (93 %) type-B hosts. Eleven of 105 (10.5 %) patients were formally diagnosed with primary immunodeficiency by a hematologist. IgG deficiency, of either low or normal value, in the face of infection comprised 91 % (30 of 34) type-A hosts and 86 % (56 of 71) type-B hosts. Six (5.7 %) patients received IgG replacement therapy. Twenty-eight patients had abnormal total complement levels (low or normal): 7.4 % (2 of 34) A hosts and 40 % (26 of 71) B hosts ( p = 0.002 ). B hosts had statistically significantly lower complement levels and significantly more no-growth cultures ( p < 0.03 ). Thirteen of 14 patients with recurrent infections had low or normal IgG levels. IgM was significantly lower between reinfected patients and those without reinfection ( p = 0.0005 ). Conclusions: Adding immunologic evaluation to the Cierny-Mader classification more accurately determines patients' true host status and better quantifies risk and outcome with respect to orthopedic infection. Immunologically deficient A hosts should be quantified as B hosts. IgG deficiencies may be addressed when deemed appropriate by the consulting hematologist/immunologist. Patients with recurrent infections had significantly lower IgM levels than their nonrecurrent infection counterparts.

PubMed Disclaimer

Conflict of interest statement

No funding was received to conduct this study. Janet D. Conway is a consultant for Zimmer Biomet, Bonesupport, and SmithNephew and receives fellowship support from Biocomposites. The spouse of Janet D. Conway receives royalties from the University of Florida. The following organizations supported the institution of Janet D. Conway, Vache Hambardzumyan, Nirav G. Patel, Shawn D. Giacobbe, and Martin G. Gesheff: Biocomposites, DePuy Synthes Companies, MHE Coalition, Orthofix, OrthoPediatrics, Pega Medical, SmithNephew, Stryker, and Zimmer Biomet. Vache Hambardzumyan, Nirav G. Patel, Nirav G. Patel, and Martin G. Gesheff do not have any other financial disclosures to report.

References

    1. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Picard C, Puck JM, Sullivan K, Tang ML. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162. doi: 10.3389/fimmu.2014.00162. - DOI - PMC - PubMed
    1. Beard LJ, Ferris L, Ferrante A. Immunoglobulin G subclasses and lymphocyte subpopulations and function in osteomyelitis and septic arthritis. Acta Paediatr Scand. 1990;79:599–604. doi: 10.1111/j.1651-2227.1990.tb11523.x. - DOI - PubMed
    1. Bloom KA, Chung D, Cunningham-Rundles C. Osteoarticular infectious complications in patients with primary immunodeficiencies. Curr Opin Rheumatol. 2008;20:480–485. doi: 10.1097/BOR.0b013e3282fd6e70. - DOI - PMC - PubMed
    1. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, Espinosa-Rosales FJ, Hammarström L, Nonoyama S, Quinti I, Routes JM, Tang ML, Warnatz K. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38–59. doi: 10.1016/j.jaip.2015.07.025. - DOI - PMC - PubMed
    1. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27:497–502. doi: 10.1007/s10875-007-9103-1. - DOI - PubMed